Drug intelligence / Profile preview

RO6889678

Development stage: Discontinued
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

RO6889678 is a highly potent small molecule inhibitor of hepatitis B virus (HBV) capsid formation. It was developed by Roche as an antiviral agent targeting HBV infection. The drug acts by inhibiting the assembly of the HBV capsid, thereby interfering with viral replication. Preclinical and early clinical studies demonstrated that RO6889678 has a complex absorption, distribution, metabolism, and excretion (ADME) profile and shows significant intracellular enrichment in hepatocytes. The compound also exhibits interactions with cytochrome P450 enzymes and UDP-glucuronosyltransferases, leading to potential drug-drug interactions when co-administered with agents like ritonavir. Development of RO6889678 has been discontinued[1][2][7].

Other names: 1578153-27-1

Targets

HBV capsid (Hepatitis B virus capsid)

Beyond the preview

Go deeper on RO6889678.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO6889678.

Explore the full profile